Payment overview · 2025
General Payments
$520.31
30 reported records · 15 companies
Healthcare provider profile · identity verified
Amer Arshad, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DEFIANCE, OH · NPI 1710970652
Verified facts
What the public records show
CMS Open Payments records show Amer Arshad, MD received $520.31 in general payments during 2025 across 30 reported records.
Dexcom, Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $100.92 | 19.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.84 | 11.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.02 | 10.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.39 | 9.1% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $37.77 | 7.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.35 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.34 | 6.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.60 | 5.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.19 | 4.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.04 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.13 | 3.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.74 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.37 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.11 | 2.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.50 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.31 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $100.92 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.02 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.74 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.60 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 188 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
188 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 130 |
| Gabapentin | Gabapentin | 469 | 127 |
| Omeprazole | Omeprazole | 435 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 119 |
| Lisinopril | Lisinopril | 428 | 136 |
| Losartan Potassium | Losartan Potassium | 426 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 132 |
| Potassium Chloride | Potassium Chloride | 374 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 111 |
| Metformin Hcl | Metformin Hcl | 337 | 112 |
| Prednisone | Prednisone | 322 | 209 |
| Furosemide | Furosemide | 297 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 284 | 96 |
| Glimepiride | Glimepiride | 272 | 82 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 256 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 75 |
| Januvia | Sitagliptin Phosphate | 224 | 53 |
| Carvedilol | Carvedilol | 223 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 69 |
| Allopurinol | Allopurinol | 214 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 64 |
| Ozempic | Semaglutide | 188 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 184 | 85 |
| Simvastatin | Simvastatin | 182 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 173 | 127 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 38 |
| Jardiance | Empagliflozin | 149 | 43 |
| Eliquis | Apixaban | 147 | 41 |
| Pregabalin | Pregabalin | 131 | 25 |
| Mounjaro | Tirzepatide | 130 | 26 |
| Spironolactone | Spironolactone | 129 | 43 |
| Buspirone Hcl | Buspirone Hcl | 128 | 40 |
| Alendronate Sodium | Alendronate Sodium | 127 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 124 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 35 |
| Trazodone Hcl | Trazodone Hcl | 114 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 113 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 25 |
| Bumetanide | Bumetanide | 102 | 33 |
| Mirtazapine | Mirtazapine | 96 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 94 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 43 |
| Celecoxib | Celecoxib | 88 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 34 |
| Sertraline Hcl | Sertraline Hcl | 83 | 26 |
| Montelukast Sodium | Montelukast Sodium | 82 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 24 |
| Azithromycin | Azithromycin | 76 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 19 |
| Warfarin Sodium | Warfarin Sodium | 74 | 18 |
| Bupropion Xl | Bupropion Hcl | 72 | 19 |
| Labetalol Hcl | Labetalol Hcl | 70 | 24 |
| Donepezil Hcl | Donepezil Hcl | 67 | 19 |
| Levofloxacin | Levofloxacin | 67 | 44 |
| Meloxicam | Meloxicam | 66 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Atenolol | Atenolol | 61 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 14 |
| Tramadol Hcl | Tramadol Hcl | 61 | 19 |
| Midodrine Hcl | Midodrine Hcl | 60 | 12 |
| Cephalexin | Cephalexin | 58 | 38 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 17 |
| Cefuroxime | Cefuroxime Axetil | 55 | 49 |
| Dexamethasone | Dexamethasone | 55 | 53 |
| Amoxicillin | Amoxicillin | 53 | 46 |
| Famotidine | Famotidine | 52 | 18 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 43 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 47 | 21 |
| Gemfibrozil | Gemfibrozil | 47 | 11 |
| Synthroid | Levothyroxine Sodium | 47 | 15 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Alprazolam | Alprazolam | 42 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 21 |
| Mometasone Furoate | Mometasone Furoate | 40 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Breyna | Budesonide/Formoterol Fumarate | 39 | 14 |
| Valsartan | Valsartan | 39 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 15 |
| Clonidine Hcl | Clonidine Hcl | 37 | 13 |
| Jantoven | Warfarin Sodium | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | 15 |
| Topiramate | Topiramate | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 17 |
| Sucralfate | Sucralfate | 34 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 14 |
| Olanzapine | Olanzapine | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 11 |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | 11 |
| Metolazone | Metolazone | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Nystatin | Nystatin | 26 | 20 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Np Thyroid | Thyroid,pork | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Temazepam | Temazepam | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.31 · 30 records | Dexcom, Inc. | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, JOURNAVX, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, XIFAXAN, YUPELRI, ZAVZPRET, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error